TFII.TO -1.7C -0.53MU 0.36CRWD 7.06PANW 5.71SNOW 21.21V -0.68MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
HOLD

Pfizer Inc(PFE)

May 15, 2008
6.5% dividend yield. Cash flows are very strong.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$20.08

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 14, 2008
Recently sold his holdings. A lot of their pipeline is going into generic distribution, which will take a lot of revenue off the top line. Feels the 6% dividend is probably safe.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.06

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 12, 2008
(A Top Pick May 18/07. Down 23%.) Have not proven to be defensive. Most of the major drug companies have more of their larger drugs coming off patent shortly. At this point, downside risk looks pretty limited. 6% plus yield. A Hold.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.91

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 08, 2008
(A Top Pick May 2/07. Down 20%.) Still in his Top 10. His model price is $34.72, a 74% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.97

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 25, 2008
The trouble he has with the big pharmaceuticals is that they are having a terribly hard time reinventing themselves. They all have good yields. The FDA right now is turning the taps off. It is harder and harder to get approval. Would be very cautious on this sector. The one exception is Johnson & Johnson (JNJ-N), which seems to have a better approach than their peers.
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$20.43

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 23, 2008
This has not been a good experience over the last year. Stock has come off pretty sharply. All of the drugs are coming off patent for the big pharmaceuticals. Trading at under 10X earnings and is still earning 35% on its equity and yielding over 6%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$19.88

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 15, 2008
US pharmaceutical sector is under tremendous pressure. Starting to see a run off in many of the product portfolios and a wind down of patent protection. With the potential change of government he expects the whole sector will be under pressure.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$20.71

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 10, 2008
Good stock to own in a bad market. 6% yield. $25 billion in cash. The bad news is known including some of the big drugs coming off of patent and the lull before some of their late stage pipe line starts to kick in.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$20.92

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 07, 2008
This is a difficult one for a value investor. The stock is down quite a bit and has a great balance sheet with a lot of cash. However, this could be a value trap. Looking forward, this company is going to be losing a lot of its primary drugs. Also, there is an election coming up and the rules may change on drug pricing.
Photo of Pat NaccaratoPat NaccaratoUnlock Rating
$21.48

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 25, 2008
Dividend over 6%. Would hold for the dividend. Wouldn’t buy.
Photo of Benj GallanderBenj GallanderUnlock Rating
$20.78

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 17, 2008
They’ve got lots of cash, therefore their dividend is safe. Not sure if they are going to be able to build their business to have significant growth.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$20.57

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Pretty cheap. Has been a dog over the last year but you are getting a 5.5% dividend. PE is 11X’s. Their patent on the Lipitor drug expires, but not for another 12 years. Cash flow from this is about 40% of their profit and they are moving into other new drugs. If the Democrats win, the question is will they get squeezed on Medicare but that is already built into the stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Trading at 10X earnings, which is the lowest he has ever seen a US pharmaceutical. They are great beneficiaries of the lower US$. Have a great international business. Have lots of cash for acquisitions.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 03, 2008
(Market Call Minute.) At this price, you can be a buyer and sell at $26 or so.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$22.25

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 27, 2008
He has a model price of $40.10, which is a 76% positive differential. Has up its dividends considerably and has positive earnings revisions.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.75

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 526 to 540 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.15$146.54
SLB -1.22$48.37
SHEL -0.92$91.06
AAPL -4.25$304.66
AMZN 12.75$284.33

Today's Top Picks

TFII.TO -1.7$13.38
C -0.53$131.92
MU 0.36$823.39
CRWD 7.06$197.92
PANW 5.71$337.54

Popular Articles

Latest Sell Signals

AAPL -4.25$304.66
AAPL -4.25$304.66
AAPL -4.25$304.66
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like